DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Halozyme
Halozyme
HY 2021 Results
Halozyme, Inc. Protocol HALO-110-101 Amendment 3 CLINICAL STUDY PROTOCOL Title
Genmab Announces Financial Results for the First Nine Months of 2020
Breaking Barriers with Pegvorhyaluronidase Alfa
Study Protocol
Faculty Disclosure
Halozyme, Inc. Protocol HALO-109-202 CONFIDENTIAL Page 1 of 128 09 February 2018 CLINICAL STUDY PROTOCOL Title
Faculty Disclosure
PEGPH20 in Addition to Nab-Paclitaxel and Gemcitabine for Metastatic Pancreatic Ductal Adenocarcinoma NIHRIO (HSRIC) ID: 7087 NICE ID: 9901
Enhanze Draws BMS, Roche Money; Halozyme Could Reap $2B+ by Randy Osborne, Staff Writer Halozyme Corp
HALOZYME THERAPEUTICS, INC. (Exact Name of Registrant As Specified in Its Charter) ______Commission File Number 001-32335
HER2 Status in Advanced Or Metastatic Gastric, Esophageal, Or Gastro-Esophageal
Form 10-Q Halozyme Therapeutics, Inc
Form 10-K Halozyme Therapeutics, Inc
Auditor Disclosure Data.Xlsx
Form 10-K Halozyme Therapeutics, Inc
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric Or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1A/B JVDF Trial
Scrip Awards 2018 Scrip in Association with Pharma Intelligence |
Top View
Open Full Page
Alexion and Halozyme Enter License Agreement for ENHANZE Technology
Faculty Disclosure
Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and Pegph20 in Advanced Breast Cancer
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
Volunteer Disclosure Report